Evidence map›Paper›PMID 36307605›Full record

ReviewCellular and molecular neurobiology2023

Involvement of the G-Protein-Coupled Estrogen Receptor-1 (GPER) Signaling Pathway in Neurodegenerative Disorders: A Review.

Shubham Upadhayay, Rishav Gupta, Surbhi Singh, Maroti Mundkar, Gursewak Singh, Puneet Kumar

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Role and Mechanisms of G protein-coupled receptors in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shubham UpadhayayDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India.
Rishav GuptaDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India.
Surbhi SinghDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India.
Maroti MundkarDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India.
Gursewak SinghDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India.
Puneet KumarDepartment of Pharmacology, Central University of Punjab, Ghudda Campus, Ghudda, Bathinda, Punjab, 151401, India. punnubansal79@gmail.com.
Central University of Punjab · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The G-protein-coupled estrogen receptor-1 (GPER) is an extranuclear estrogen receptor that regulates the expression of several downstream signaling pathways with a variety of biological actions including cell migration, proliferation, and apoptosis in different parts of the brain area. It is endogenously activated by estrogen, a steroidal hormone that binds to GPER receptors which help in maintaining cellular homeostasis and neuronal integrity as well as influences neurogenesis. In contrast, neurodegenerative disorders are a big problem for society, and still many people suffer from motor and cognitive impairments. Research to date reported that GPER has the potential to whittle down motor abnormalities and cognitive dysfunction by limiting the progression of neurodegenerative disorders. Although several findings suggest that GPER activation accelerated transcription of the PI3K/Akt/Gsk-3β and ERK1/2 signaling pathway that halt disease progression by decreasing oxidative stress, neuroinflammation, and apoptosis. Accordingly, the goal of this review is to highlight the basic mechanism of GPER signaling pathway-mediated neuroprotection in various neurodegenerative disorders including Parkinson's disease (PD), Huntington's disease (HD), Tardive dyskinesia (TD), and Epilepsy. This review also discusses the role of the GPER activators which might be a promising therapeutic target option to treat neurodegenerative disorders. All the data were obtained from published articles in PubMed (353), Web of Science (788), and Scopus (770) databases using the search terms: GPER, PD, HD, TD, epilepsy, and neurodegenerative disorders.

Indexed as

Neurodegenerative DiseasesParkinson DiseaseGlycogen Synthase Kinase 3 betaGTP-Binding ProteinsHumansPhosphatidylinositol 3-KinasesReceptors, EstrogenReceptors, G-Protein-CoupledSignal TransductionGlycogen Synthase Kinase 3 betaGTP-Binding ProteinsPhosphatidylinositol 3-KinasesReceptors, EstrogenReceptors, G-Protein-CoupledEpilepsyG-protein-coupled estrogen receptor-1 (GPER)Huntington’s disease (HD)NeuroprotectionParkinson’s diseases (PD)Tardive dyskinesia (TD)

Identifiers

PMID36307605
PMCPMC11412173
OpenAlexW4307475965

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.